Publicaciones en colaboración con investigadores/as de Icahn School of Medicine at Mount Sinai (16)

2024

  1. Developmental or Procedural Vena Cava Interruption and Venous Thromboembolism: A Review

    Seminars in Thrombosis and Hemostasis, Vol. 50, Núm. 6, pp. 851-865

  2. Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease

    Nature Reviews Cardiology, Vol. 21, Núm. 8, pp. 574-592

  3. When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review

    Journal of the American College of Cardiology, Vol. 83, Núm. 3, pp. 444-465

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Atorvastatin versus Placebo in ICU Patients with COVID-19: Ninety-day Results of the INSPIRATION-S Trial

    Thrombosis and haemostasis, Vol. 123, Núm. 7, pp. 723-733

  3. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  4. Inhibition of thrombin-activatable fibrinolysis inhibitor via DS-1040 to accelerate clot lysis in patients with acute pulmonary embolism: a randomized phase 1b study

    Journal of Thrombosis and Haemostasis, Vol. 21, Núm. 10, pp. 2929-2940

2022

  1. Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial

    The BMJ, Vol. 376

  2. Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review

    JAMA Cardiology, Vol. 7, Núm. 7, pp. 747-759

2021

  1. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality among Patients with COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial

    JAMA - Journal of the American Medical Association, Vol. 325, Núm. 16, pp. 1620-1630

  2. Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial

    Thrombosis and Haemostasis, Vol. 122, Núm. 1, pp. 131-141

  3. Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review

    Journal of the American College of Cardiology, Vol. 78, Núm. 16, pp. 1635-1654

  4. Mapping the human genetic architecture of COVID-19

    Nature, Vol. 600, Núm. 7889, pp. 472-477

  5. Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review

    Journal of the American College of Cardiology, Vol. 77, Núm. 15, pp. 1903-1921

2020

  1. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review

    Journal of the American College of Cardiology, Vol. 75, Núm. 23, pp. 2950-2973

  2. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research

    Thrombosis and Haemostasis, Vol. 120, Núm. 7, pp. 1004-1024